^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    misitatug blivedotin (RC88)

    i
    Associations
    News

    Trials

    Company:
    Rongchang Pharma
    Drug class:
    Microtubule inhibitor, Mesothelin-targeted antibody-drug conjugate
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours (NCT05804526)
    Phase 1/2
    RemeGen Co., Ltd.
    Recruiting
    Last update posted :
    04/30/2024
    Initiation :
    07/19/2023
    Primary completion :
    05/01/2025
    Completion :
    12/01/2025
    MSLN
    |
    MSLN positive
    |
    Tyvyt (sintilimab) • Loqtorzi (toripalimab-tpzi) • misitatug blivedotin (RC88)
    A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors (NCT04175847)
    Phase 1/2
    RemeGen Co., Ltd.
    Recruiting
    Last update posted :
    02/20/2024
    Initiation :
    04/14/2020
    Primary completion :
    09/30/2024
    Completion :
    09/01/2025
    MSLN
    |
    misitatug blivedotin (RC88)
    A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours (NCT05508334)
    Phase 1
    RemeGen Co., Ltd.
    Recruiting
    Last update posted :
    01/10/2024
    Initiation :
    01/30/2023
    Primary completion :
    06/30/2024
    Completion :
    12/30/2024
    MSLN
    |
    MSLN expression
    |
    misitatug blivedotin (RC88)